Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate

Background: Clinically stable multiple sclerosis (MS) patients on long-term therapy often have negligible acute inflammation on MRI. Brain atrophy may provide insight into subclinical disease progression in such populations.Objective: This study aims to compare brain atrophy for age- and gender-matc...

Full description

Bibliographic Details
Main Authors: Justin M. Honce, Kavita V. Nair, Brian D. Hoyt, Rebecca A. Seale, Stefan Sillau, Eric Engebretson, Brittany Schurr, John R. Corboy, Timothy L. Vollmer, Enrique Alvarez
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Neurology
Subjects:
multiple sclerosis
brain atrophy
comparative effectiveness
fingolimod
glatiramer acetate
percent brain volume change
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.01045/full

Internet

https://www.frontiersin.org/article/10.3389/fneur.2020.01045/full

Similar Items